论文部分内容阅读
对经X线骨密度仪检测L2～4的骨密度（BMD）诊断为绝经后骨质疏松（PMO）的86例妇女的血清雌二醇（E2）含量进行RIA测定．其E2含量均值为61．38pmol／L。对本组86例PMO妇女给予小剂量利维爱为主的联合用药治疗6个月．对照观察用药前后BMD、血清钙（Ca）、磷（P）、碱性磷酸酶（ALP）的变化。结果显示．用药后BMD均有不同程度的提高．以绝经时间≤10年者尤为明显（P＜0.01）；绝经时间＞10年者虽有提高．但差异不显著（P＞0.05）。治疗前血清Ca增高30例．占34.88％；P降低29例．占33.72％；ALP增高51例．占59．3％。治疗后均恢复正常。提示联合用药可减少利维爱的用量，是PMO较为理想的治疗方案。绝经后任何时期用药都可防止骨的继续丢失，早期治疗效果更好。
The serum estradiol (E2) levels of 86 women diagnosed as postmenopausal osteoporosis (PMO) by bone mineral density (BMD) of L2-4 by X-ray absorptiometry were measured by RIA. The average E2 content of 61.38pmol / L. This group of 86 PMO women given a small dose of Levi-based combination therapy for 6 months. The changes of BMD, serum calcium (Ca), phosphorus (P) and alkaline phosphatase (ALP) were observed before and after treatment. The results show. After treatment BMD have different degrees of improvement. In menopausal time ≤ 10 years was particularly evident (P <0.01); menopausal> 10 years although the increase. But the difference was not significant (P> 0.05). Serum Ca increased before treatment in 30 cases. Accounting for 34.88%; P decreased in 29 cases. Accounting for 33.72%; ALP increased in 51 cases. Accounting for 59.3%. After treatment, returned to normal. Tip combination therapy can reduce the amount of love Lee, PMO is the ideal treatment. Medication at any time after menopause can prevent the continued loss of bone, early treatment is better.